复发难治多发性骨髓瘤中序贯BCMA CAR-T细胞治疗
该研究在3个医疗中心分析10例经商业获批的idecabtagene vicleucel治疗后复发的复发难治多发性骨髓瘤患者,复发后均接受ciltacabtagene autoleucel作为第二次CAR-T输注。序贯BCMA CAR-T治疗安全,无更高级别免疫细胞相关副作用或新安全信号,第二次治疗后6个月估计无进展生存率为64.8%(95%CI 39%-100%),首次CAR-T疗效持续时间可预测第二次的持久缓解。
要点
- 序贯两种商业获批BCMA CAR-T产品安全,未出现更高级别免疫细胞相关副作用或新安全信号
- 第二次CAR-T后总缓解率100%(至少VGPR),60%达MRD阴性,6个月估计PFS 64.8%
- 首次CAR-T疗效持续时间可预测第二次CAR-T的持久缓解
核心结论
- 据作者所知,本研究首次提供真实世界证据表明序贯使用两种不同商业获批BCMA CAR-T产品既可行又有效,尤其在首次BCMA CAR-T治疗缓解持久的患者中。
研究设计与样本
- 在3个医疗中心分析10例经重度预处理的复发难治多发性骨髓瘤患者,均接受商业获批的idecabtagene vicleucel治疗,复发后均接受ciltacabtagene autoleucel作为第二次CAR-T输注,两次治疗间允许桥接治疗。
主要发现
- 序贯BCMA CAR-T治疗安全,无更高级别免疫细胞相关副作用或新安全信号。
- 观察到稳健的CAR-T细胞扩增和高缓解率:100%达至少VGPR,60%达MRD阴性。
- 第二次CAR-T治疗后6个月估计无进展生存率为64.8%(95%CI 39%-100%)。
- 首次CAR-T治疗的缓解持续时间可预测第二次CAR-T产品的持久缓解。
- ciltacabtagene autoleucel后复发的3例中仅1例出现BCMA抗原丢失;3例复发者中2例一年内死亡,且对双特异性抗体治疗无进一步缓解。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Multiple myeloma (MM) relapsing after B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell treatment remains a therapeutic challenge. Data on re-exposure to CAR T-cell therapy targeting the same antigen are scarce. We analyzed 10 heavily pretreated patients with RRMM at 3 medical centers treated with the commercially approved CAR T-cell therapy product idecabtagene vicleucel in a real-world setting. Upon relapse, all patients received ciltacabtagene autoleucel as a second CAR T-cell therapy infusion, with bridging treatments permitted between both therapies. Sequential therapy with BCMA-directed CAR T-cell therapy was safe, with no higher-grade immune-cell-associated side effects or new safety signals. We found robust CAR T-cell therapy expansion and high response rates (100% with at least very good partial response, with 60% achieving minimal residual disease negativity), with an estimated progression-free survival of 64.8% (95% confidence interval, 39%-100%) at 6 months after the second CAR T-cell treatment. Duration of response to first CAR T-cell therapy was predictive for durable responses to the second CAR T-cell therapy product. Loss of BCMA antigen occurred in only 1 of 3 patients relapsing after ciltacabtagene autoleucel. Two of three relapsing patients died within a year, and showed no further response to bispecific antibody treatment. To our knowledge, this study provides the first real-world evidence that sequential treatment with 2 different commercially approved BCMA CAR T-cell therapy products is both feasible and effective, particularly in patients with prolonged responses to initial BCMA CAR T-cell therapy.
引用
- Richardson T, Holtick U, Frenking JH, et al. Sequential BCMA CAR T-cell therapy in refractory multiple myeloma. Blood Adv. 2025. PMID: 40644619. doi:10.1182/bloodadvances.2025016712
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。